inOpportunities, Phase 3

Company with sleep apnea asset seeks development partner

First sleep apnea oral therapy available for co-development. Phase II study completed with positive results. Company has completed first round of financing raising $40 million. Market is highly unsatisfied. Strong IP protection through 2039.

Company seeks $120 million to complete Phase III clinical trials.

See Below for More

inOpportunities, Phase 3

505(b)(2) formulation for chemotherapy available in-licensing

505(b)(2) formulation for the treatment of chemotherapy induced nausea and vomiting. Multiple advantages over currently available products including the ability to use without further reconstitution.

505(b)(2) formulation for schizophrenia available in-licensing

505(b)(2) formulation for schizophrenia available for in-licensing:

Oral Solid Dose (OSD) Tablets & Capsules facility Sale

Oral Solid Dose (OSD) Tablets & Capsules facility, 45 minutes from Boston, with $20 million in facility value / equipment. Asset Overview Opportunity

Nanoparticle Processing Technology Company Immediate Acquisition

University-owned high-throughput, nanoparticle processing technology company. Continuous Manufacturing of Nanomedicines: Ready for Immediate Acquisition

Self-amplifying RNA (saRNA) Virtual Biotech seeks VC

Self-amplifying RNA (saRNA) Virtual Biotech seeks VC investment to develop a pipeline of RNA therapeutics and vaccines.

Phase III plasma-derived Therapeutic Company Raise Capital

Private-Equity owned, Phase III plasma-derived therapeutic company is ready to build the commercial facility with One Million Liter annual capacity, in Dallas Texas Looking to Raise Capital

Non-cGMP API Starting Material Company Asset Opportunity

Non-cGMP API Drug Development Starting Materials + API Pilot Plant and cGMP CDMO: Ready for Immediate Acquisition with operations in Jaipur, India and Birmingham, Alabama

Approved 505(b)(2) available for in-licensing

Approved 505(b)(2) available for in-licensing: CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space. US rights only.

Marketed products in the GI space

Marketed product in the GI space (idiopathic bowel syndrome, diarrhea, opioid induced constipation) available for acquisition. Client will also consider a distribution partnership.

Questions? Feel free to contact us!

Call (615) 887-3847

We appreciate your interest!  Please get in touch and we will contact you directly.

Services and Partnership Opportunities

  • Pharmaceutical BD&L
  • Pharma BD&L
  • Pharmaceutical business development
  • ANDAs for sale
  • ANDA licensing
  • Pharmaceutical in-licensing
  • Pharmaceutical out-licensing
  • 505(b)(2) for sale
  • Pharma in-licensing
  • Pharma out-licensing
  • Oncology company for sale
  • Oncology sales force
  • Pharma distribution deals
  • Branded generics for sale
  • Pharmaceutical partnering companies
  • Pharmaceutical development deals
  • Pharma commercialization consulting
  • Head and neck cancer assets available for licensing
  • Pharmaceutical deal arrangers
  • Pharma manufacturing facilities finders
  • Pharmaceutical authorized generic products available

 

Commercial Healthcare Partners

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Commercial Healthcare Partners and while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

About | Services| Contact | Privacy Policy

Chemotherapy induced nausea and vomiting product available for in-licensingManufacturing facilities needed